MARIA RITA DE FIGUEIREDO LEMOS BORTOLOTTO

(Fonte: Lattes)
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/57 - Laboratório de Fisiologia Obstétrica, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 6 de 6
  • conferenceObject
    Placental abruption and thrombophilia
    (2013) ARISSA, K.; BARROS, V. V.; BAPTISTA, F. S.; BORTOLOTTO, M. R. D. F. L.; V, R. P. Francisco; ZUGAIB, M.
  • article 8 Citação(ões) na Scopus
    Can thrombophilia worsen maternal and perinatal outcomes in cases of severe preeclampsia?
    (2018) BAPTISTA, Fernanda Spadotto; BORTOLOTTO, Maria Rita de Figueiredo Lemos; BIANCHINI, Fabiola Roberta Marim; KREBS, Vera Lucia Jornada; ZUGAIB, Marcelo; FRANCISCO, Rossana Pulcinelli Vieira
    Objective: To evaluate whether thrombophilia worsens maternal and foetal outcomes among patients with severe preeclampsia (PE). Method: From October 2009 to October 2014, an observational retrospective cohort study was performed on pregnant women with severe PE diagnosed before 34 weeks of gestation and their newborns hospitalized at the Clinics Hospital, FMUSP. Patients who had no heart disease, nephropathies, pre-gestational diabetes, gestational trophoblastic disease, foetal malformation, or twin pregnancy and who underwent thrombophilia screening during the postnatal period were included. New pregnancies of the same patient; cases of foetal morphological, genetic, or chromosomal abnormalities after birth; and women who used heparin or acetylsalicylic acid during pregnancy were excluded. Factor V Leiden, G20210A prothrombin mutation, antithrombin, protein C, protein S, homocysteine, lupus anticoagulant, and anticardiolipin IgG and IgM antibodies were analysed. The groups with and without thrombophilia were compared regarding their maternal clinical and laboratory parameters and perinatal outcomes. Results: Of the 127 patients selected, 30 (23.6%) had thrombophilia (hereditary or acquired). We found more white patients in thrombophilia group (p = .036). Analysis of maternal parameters showed a tendency of thrombophilic women to have more thrombocytopenia (p = .056) and showed worsening of composite laboratory abnormalities (aspartate aminotransferase >= 70 mg/dL, alanine aminotransferase >= 70 mg/dL, platelets < 100,000/mm(3), serum creatinine >= 1.1 mg/dL; p = .017). There were no differences in foetal perinatal outcomes. Conclusion: The presence of thrombophilia leads to worsening of maternal laboratory parameters among patients with severe forms of PE but without worsening perinatal outcomes.
  • conferenceObject
    IMPACT OF PREVIOUS HYPERTENSIVE DISORDER DURING PREGNANCY ON ANTHROPOMETRIC MEASUREMENTS, 24-HOUR BLOOD PRESSURE AND ARTERIAL STIFFNESS
    (2021) VERARDINO, Renata; RODRIGUES, Sara; BERGER, Ana; COSTA-HONG, Valeria; MACEDO, Thiago; BAPTISTA, Fernanda; BORTOLOTTO, Maria; FRANCISCO, Rossana; ZUGAIB, Marcelo; BORTOLOTTO, Luiz
  • conferenceObject
    Obstetrics outcomes associated with an increased level of lipoprotein-a (LP-a) in thrombophilic patients
    (2013) RECCHI, D.; BARROS, V. V.; BAPTISTA, F. S.; BORTOLOTTO, M. R. D. F. L.; V, R. P. Francisco; ZUGAIB, M.
  • conferenceObject
    Low levels of vitamin d in pregnant women with thromboembolism/thrombophilia
    (2013) GALLO, L.; BARROS, V. V.; BAPTISTA, F. S.; BORTOLOTTO, M. R. D. F. L.; V, R. P. Francisco; ZUGAIB, M.
  • article 1 Citação(ões) na Scopus
    Venous thromboembolism risk score during hospitalization in pregnancy: results of 10694 prospective evaluations in a clinical trial
    (2023) BARROS, Venina Isabel Poco Viana Leme de; IGAI, Ana Maria Kondo; BAPTISTA, Fernanda Spadotto; BORTOLOTTO, Maria Rita de Figueiredo Lemos; PERES, Stela Verzinhasse; FRANCISCO, Rossana Pulcinelli Vieira
    Objectives: Hospitalization during pregnancy and childbirth increases the risk of Venous Thromboembolism Risk (VTE). This study applied a VTE risk score to all hospitalized pregnant women to ascertain its effectiveness in pre -venting maternal death from VTE until 3 months after discharge.Methods: In this interventional study, patients were classified as low-or high-risk according to the VTE risk score (Clinics Hospital risk score). High-risk patients (score & GE; 3) were scheduled for pharmacological Thromboprophy-laxis (TPX). Interaction analysis of the main risk factors was performed using Odds Ratio (OR) and Poisson regres-sion with robust variance.Results: The data of 10694 cases (7212 patients) were analyzed; 1626 (15.2%, 1000 patients) and 9068 (84.8%, 6212 patients) cases were classified as high-risk (score & GE; 3) and low-risk (score < 3), respectively. The main risk factors (Odds Ratio, 95% Confidence Interval) for VTE were age & GE; 35 and < 40 years (1.6, 1.4-1.8), parity & GE; 3 (3.5, 3.0-4.0), age & GE; 40 years (4.8, 4.1-5.6), multiple pregnancies (2.1, 1.7-2.5), BMI & GE; 40 kg/m2 (5.1, 4.3-6.0), severe infection (4.1, 3.3-5.1), and cancer (12.3, 8.8-17.2). There were 10 cases of VTE: 7/ 1636 (0.4%) and 3/9068 (0.03%) in the high-and low-risk groups, respectively. No patient died of VTE. The inter-vention reduced the VTE risk by 87%; the number needed to treat was 3.Conclusions: This VTE risk score was effective in preventing maternal deaths from VTE, with a low indication for TPX. Maternal age, multiparity, obesity, severe infections, multiple pregnancies, and cancer were the main risk factors for VTE.